Trident Lifeline reported H2FY26 revenue growth of 47% YoY to ₹58.16 crore and full-year FY26 revenue crossing ₹100 crore for the first time.
The company maintains 27% EBITDA margin with PAT reaching ₹96.76 lakh in H2FY26, up 46% YoY, driven by domestic and export market expansion.
Operates a hybrid manufacturing model with 1,091 product registrations across 46 countries and 2,534 additional registrations in pipeline for future growth.
Strategic focus includes investments in manufacturing assets, off-patent molecules, and expanding therapeutic portfolio across tablets, capsules, and other formulations.